MNV
Market News Video
MNV MNV 10 Oversold Stocks You Need To Know About
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

See How Amedisys Ranks Among Analysts' Top Picks With Strong Buyback Activity
Tuesday, January 28, 1:17 PM ET, by Market News Video Staff

A study of analyst recommendations at the major brokerages shows that Amedisys, Inc. (AMED) is ...

IWM, LITE, AMED, HAE: ETF Inflow Alert
Friday, February 14, 11:09 AM ET, by Market News Video Staff

Symbols mentioned in this story: IWM, LITE, AMED, HAE Exchange traded funds (ETFs) trade just ...

Noteworthy Tuesday Option Activity: TWLO, AMED, SFIX
Tuesday, February 18, 3:17 PM ET, by Market News Video Staff

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...

Snatch This Bargain Even Cheaper Than Director Capps Did
Monday, March 2, 10:07 AM ET, by Market News Video Staff

There's an old saying on Wall Street about insider buying: there are many possible reasons ...

Look Under The Hood: RXL Has 18% Upside
Wednesday, March 4, 8:46 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Top Buys by Directors: Perkins's $335K Bet on AMED

By Market News Video Staff, Tuesday, September 29, 11:23 AM ET
Play Video: One Reason For Insiders to Buy


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So in this series we look at the largest insider buys by company directors over the trailing six month period, one of which was a total of $335K by Bruce D. Perkins, Director at Amedisys, Inc. (NASDAQ:AMED).

Perkins bets big on AMED:

Purchased Insider Title Shares Price/Share Value
06/12/2020 Bruce D. Perkins Director 2,000 $167.48 $334,960.00

Perkins's average cost works out to $167.48/share. Shares of Amedisys, Inc. were changing hands at $232.22 at last check, trading off about 0.1% on Tuesday. The chart below shows the one year performance of AMED shares, versus its 200 day moving average:

Amedisys, Inc. Chart

Looking at the chart above, AMED's low point in its 52 week range is $121.37 per share, with $248.955 as the 52 week high point — that compares with a last trade of $232.22.


Special Offer: Receive our best dividend ideas directly to your inbox each afternoon with the Dividend Channel Premium Newsletter


This Article's Word Cloud:   AMED   Amedisys   Bruce   Buys   Channel   Company   Director   Directors   Dividend   Insider   Looking   Newsletter   Offer   Perkins   Premium   Presumably   Price   Purchased   Receive   Share   Shares   Special   Start   Title   Tuesday   Value   about   above   afternoon   average   below   best   bets   both   buys   chart   company   directors   last   make   maybe   mdash   point   share   stock   take   that   they   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Top Buys by Directors: Perkins's $335K Bet on AMED | Market News Video | Copyright © 2008 - 2021, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.